N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas

Lucas Moretti, L. Jeffrey Medeiros, Kranthi Kunkalla, Michelle D. Williams, Rajesh R. Singh, Francisco Vega

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Recently, reports using immunohistochemistry and a polyclonal antibody directed against the N-terminal region of PAX8 describe PAX8 expression in malignant lymphomas. As the N-terminal regions of PAX family members, including the B-cell transcription factor PAX5, have high sequence homology, we investigated PAX8 positivity in malignant lymphomas. Comparative sequence analysis between the N-and C-terminal regions of PAX8 and PAX5 proteins confirmed homologies of 70% and 39%, respectively. We then compared the results using N-terminal (high homology) and C-terminal (lower homology) anti-PAX8 antibodies to assess PAX8 expression in reactive tissues, diffuse large B-cell lymphoma and classical Hodgkin lymphoma, using routine immunohistochemical methods. Expression of PAX8 was also assessed in diffuse large B-cell lymphoma and classical Hodgkin lymphoma cell lines using real-time qRT-PCR methods. Our results show that reactive and neoplastic B-cells are positive for PAX8 using the N-terminal antibody, but negative for PAX8 when the C-terminal antibody was used. PAX8 mRNA levels were not detected in any of the B-cell lymphoma cell lines studied. These results indicate that benign and malignant B-cells do not express PAX8. We conclude that positivity for PAX8 reported by others in B-cell lymphomas is likely due to cross-reactivity between the N-terminal regions of PAX8 and PAX5, due to the high sequence homology of these two regions.

Original languageEnglish
Pages (from-to)231-236
Number of pages6
JournalModern Pathology
Volume25
Issue number2
DOIs
StatePublished - Feb 1 2012
Externally publishedYes

Fingerprint

Lymphoma
B-Lymphocytes
Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Sequence Homology
Hodgkin Disease
Antibodies
PAX5 Transcription Factor
Cell Line
Sequence Analysis
Real-Time Polymerase Chain Reaction
Anti-Idiotypic Antibodies
Immunohistochemistry
Messenger RNA
Proteins

Keywords

  • B-cell lymphomas
  • cross-reactivity
  • immunohistochemistry
  • PAX5
  • PAX8

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. / Moretti, Lucas; Medeiros, L. Jeffrey; Kunkalla, Kranthi; Williams, Michelle D.; Singh, Rajesh R.; Vega, Francisco.

In: Modern Pathology, Vol. 25, No. 2, 01.02.2012, p. 231-236.

Research output: Contribution to journalArticle

Moretti, Lucas ; Medeiros, L. Jeffrey ; Kunkalla, Kranthi ; Williams, Michelle D. ; Singh, Rajesh R. ; Vega, Francisco. / N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. In: Modern Pathology. 2012 ; Vol. 25, No. 2. pp. 231-236.
@article{2715e913c7ed47029d448cc12d7b5c18,
title = "N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas",
abstract = "Recently, reports using immunohistochemistry and a polyclonal antibody directed against the N-terminal region of PAX8 describe PAX8 expression in malignant lymphomas. As the N-terminal regions of PAX family members, including the B-cell transcription factor PAX5, have high sequence homology, we investigated PAX8 positivity in malignant lymphomas. Comparative sequence analysis between the N-and C-terminal regions of PAX8 and PAX5 proteins confirmed homologies of 70{\%} and 39{\%}, respectively. We then compared the results using N-terminal (high homology) and C-terminal (lower homology) anti-PAX8 antibodies to assess PAX8 expression in reactive tissues, diffuse large B-cell lymphoma and classical Hodgkin lymphoma, using routine immunohistochemical methods. Expression of PAX8 was also assessed in diffuse large B-cell lymphoma and classical Hodgkin lymphoma cell lines using real-time qRT-PCR methods. Our results show that reactive and neoplastic B-cells are positive for PAX8 using the N-terminal antibody, but negative for PAX8 when the C-terminal antibody was used. PAX8 mRNA levels were not detected in any of the B-cell lymphoma cell lines studied. These results indicate that benign and malignant B-cells do not express PAX8. We conclude that positivity for PAX8 reported by others in B-cell lymphomas is likely due to cross-reactivity between the N-terminal regions of PAX8 and PAX5, due to the high sequence homology of these two regions.",
keywords = "B-cell lymphomas, cross-reactivity, immunohistochemistry, PAX5, PAX8",
author = "Lucas Moretti and Medeiros, {L. Jeffrey} and Kranthi Kunkalla and Williams, {Michelle D.} and Singh, {Rajesh R.} and Francisco Vega",
year = "2012",
month = "2",
day = "1",
doi = "10.1038/modpathol.2011.162",
language = "English",
volume = "25",
pages = "231--236",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas

AU - Moretti, Lucas

AU - Medeiros, L. Jeffrey

AU - Kunkalla, Kranthi

AU - Williams, Michelle D.

AU - Singh, Rajesh R.

AU - Vega, Francisco

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Recently, reports using immunohistochemistry and a polyclonal antibody directed against the N-terminal region of PAX8 describe PAX8 expression in malignant lymphomas. As the N-terminal regions of PAX family members, including the B-cell transcription factor PAX5, have high sequence homology, we investigated PAX8 positivity in malignant lymphomas. Comparative sequence analysis between the N-and C-terminal regions of PAX8 and PAX5 proteins confirmed homologies of 70% and 39%, respectively. We then compared the results using N-terminal (high homology) and C-terminal (lower homology) anti-PAX8 antibodies to assess PAX8 expression in reactive tissues, diffuse large B-cell lymphoma and classical Hodgkin lymphoma, using routine immunohistochemical methods. Expression of PAX8 was also assessed in diffuse large B-cell lymphoma and classical Hodgkin lymphoma cell lines using real-time qRT-PCR methods. Our results show that reactive and neoplastic B-cells are positive for PAX8 using the N-terminal antibody, but negative for PAX8 when the C-terminal antibody was used. PAX8 mRNA levels were not detected in any of the B-cell lymphoma cell lines studied. These results indicate that benign and malignant B-cells do not express PAX8. We conclude that positivity for PAX8 reported by others in B-cell lymphomas is likely due to cross-reactivity between the N-terminal regions of PAX8 and PAX5, due to the high sequence homology of these two regions.

AB - Recently, reports using immunohistochemistry and a polyclonal antibody directed against the N-terminal region of PAX8 describe PAX8 expression in malignant lymphomas. As the N-terminal regions of PAX family members, including the B-cell transcription factor PAX5, have high sequence homology, we investigated PAX8 positivity in malignant lymphomas. Comparative sequence analysis between the N-and C-terminal regions of PAX8 and PAX5 proteins confirmed homologies of 70% and 39%, respectively. We then compared the results using N-terminal (high homology) and C-terminal (lower homology) anti-PAX8 antibodies to assess PAX8 expression in reactive tissues, diffuse large B-cell lymphoma and classical Hodgkin lymphoma, using routine immunohistochemical methods. Expression of PAX8 was also assessed in diffuse large B-cell lymphoma and classical Hodgkin lymphoma cell lines using real-time qRT-PCR methods. Our results show that reactive and neoplastic B-cells are positive for PAX8 using the N-terminal antibody, but negative for PAX8 when the C-terminal antibody was used. PAX8 mRNA levels were not detected in any of the B-cell lymphoma cell lines studied. These results indicate that benign and malignant B-cells do not express PAX8. We conclude that positivity for PAX8 reported by others in B-cell lymphomas is likely due to cross-reactivity between the N-terminal regions of PAX8 and PAX5, due to the high sequence homology of these two regions.

KW - B-cell lymphomas

KW - cross-reactivity

KW - immunohistochemistry

KW - PAX5

KW - PAX8

UR - http://www.scopus.com/inward/record.url?scp=84856539291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856539291&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2011.162

DO - 10.1038/modpathol.2011.162

M3 - Article

C2 - 22037256

AN - SCOPUS:84856539291

VL - 25

SP - 231

EP - 236

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 2

ER -